Team members for the Biocina
Mark W. Womack is BioCina’s Chief Executive Officer and is responsible for all aspects of BioCina’s performance, development, and growth, including defining the vision and strategies for the business. Mark is an organization builder with a track record of delivering unprecedented growth and profit in every role. In Mark’s most recent role prior to BioCina, […]
Michael Tsaconas is BioCina’s Vice President and General Manager. Michael is a seasoned executive with more than 20 years experience in pharmaceutical manufacturing of liquids, creams, solid oral dose forms and large molecule drug substance at companies including FH Faulding, Mayne Pharma, Hospira and most recently Pfizer. Michael has worked in the areas of Quality
Jan Bekker is BioCina’s Vice President Business Development and Commercial Operations. Jan is a biopharmaceutical industry professional with over 20 years academic and industry experience with previous roles at Pfizer, Hospira, Centre for Marine Bioproducts Development, Stellenbosch University, and the Queensland University of Technology. Jan’s significant industry experience and technical knowledge allows him to tailor
Anthony Morgan is BioCina’s Director of Operations. Anthony is a seasoned professional with 23 years of experience in the biopharmaceutical manufacturing industry, including Life Technologies, Invitrogen, Hospira and Pfizer. He has held positions in project management, business development, leading manufacturing operations and general management of operations and facilities. Anthony’s broad experience and strong project management
Melissa El Khouri is BioCina’s Head of Quality. Melissa drives for right-sized quality processes, to maintain the highest quality standards and cost-effective service. Melissa has over 10 years of experience in Quality, including previous roles at Hospira and Pfizer. Her strong engineering and validation technical skills support her quality decision making and support of management
Jane Slobedman is BioCina’s Associate Director of Program Management. Jane has more than 25 years of experience in the Pharma industry, spending the last 13 years working as a program manager for biopharmaceutical projects, partnering with in-house and CDMO clients to bring projects from early-stage development to commercialisation. Jane has worked in both drug product
Dr. Massih Tayebi is Founding Partner and Chairman of the Bridgewest Group. Massih and his brother and Co-founder Masood, create novel businesses with leading-edge processes and technology. Inspired by deep tech, Massih incorporates AI with semiconductor tech and software platforms to enable disruptive new solutions. His vision for creating a better tomorrow drives much of
Dr. Masood Tayebi is a Founding Partner and the CEO of the Bridgewest Group. He has a wealth of experience commercializing new technology, particularly in pharmaceutical and biotechnology sectors, as well as the wireless communications sectors. Dr. Tayebi is directly responsible for managing Bridgewest investments in biotechnology and pharmaceuticals, hi-tech and wireless technologies, and software.
Rick Hancock was appointed to the Board of Directors as Executive Chairman in January 2022. Rick has worked in the Biotechnology Industry for over 35 years, including 20 years with various CDMOs in operational and executive roles. Most recently, he served as Interim President and CEO at Avid Bioservices and prior to that, as President
Mike Cicio has worked in the Biotechnology Industry for over 30 years as a hands-on executive with experience with both world class innovators and CDMOs. Experienced in general management of clinical and commercial biotechnology business with a focus on operations. Mike has extensive experience in a variety of biotechnology platforms. Mike received a BS in
